Literature DB >> 8931714

Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene?

R Kruse1, C Lamberti, Y Wang, C Ruelfs, A Bruns, C Esche, P Lehmann, T Ruzicka, A Rütten, W Friedl, P Propping.   

Abstract

The Muir-Torre syndrome (MTS) is a rare autosomal-dominant condition characterized by the occurrence of sebaceous skin lesions and internal tumours in a patient. It has been demonstrated that at least a subgroup of MTS exhibits clinical and molecular genetic features of hereditary nonpolyposis colorectal cancer, including microsatellite instability in skin and visceral tumours, because of mutations in DNA mismatch repair genes. We have identified germline mutations in the hMSH2 gene in two unrelated MTS patients ascertained because of their skin tumours. Our results, together with published MTS cases, support the hypothesis that MTS with its characteristic skin lesions is confined to mutations in the hMSH2 gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931714     DOI: 10.1007/s004390050298

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  13 in total

1.  An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation.

Authors:  Angela Arnold; Stewart Payne; Samantha Fisher; Diane Fricker; Judith Soloway; Susan M White; Marco Novelli; Kylie MacDonald; James Mackay; Richard Groves; Natalie Canham
Journal:  Fam Cancer       Date:  2007-02-24       Impact factor: 2.375

2.  Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation.

Authors:  H R Murphy; R Armstrong; D Cairns; K L Greenhalgh
Journal:  Fam Cancer       Date:  2008-01-31       Impact factor: 2.375

Review 3.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

4.  Identification of Fhit as a post-transcriptional effector of Thymidine Kinase 1 expression.

Authors:  Daniel L Kiss; Catherine E Waters; Iman M Ouda; Joshua C Saldivar; Jenna R Karras; Zaynab A Amin; Seham Mahrous; Teresa Druck; Ralf A Bundschuh; Daniel R Schoenberg; Kay Huebner
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-14       Impact factor: 4.490

5.  Microsatellite instability-a useful diagnostic tool to select patients at high risk for hereditary non-polyposis colorectal cancer: a study in different groups of patients with colorectal cancer.

Authors:  C Lamberti; R Kruse; C Ruelfs; R Caspari; Y Wang; M Jungck; M Mathiak; H R Malayeri; W Friedl; T Sauerbruch; P Propping
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

6.  Hereditary colon cancer: lynch syndrome.

Authors:  Eunjeong Jang; Daniel C Chung
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

7.  First case report of Muir-Torre syndrome associated with non-small cell lung cancer.

Authors:  L Nolan; D Eccles; E Cross; G Crawford; N Beck; A Bateman; C Ottensmeier
Journal:  Fam Cancer       Date:  2009-05-16       Impact factor: 2.375

8.  Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations.

Authors:  P Peltomäki; X Gao; J P Mecklin
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

9.  Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria.

Authors:  R Kruse; A Rütten; C Lamberti; H R Hosseiny-Malayeri; Y Wang; C Ruelfs; M Jungck; M Mathiak; T Ruzicka; W Hartschuh; M Bisceglia; W Friedl; P Propping
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

10.  Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme.

Authors:  Deric M Park; Gabrielle A Yeaney; Ronald L Hamilton; Jennifer Mabold; Nikki Urban; Leonard Appleman; John Flickinger; Frank Lieberman; Arlan Mintz
Journal:  Neuro Oncol       Date:  2008-11-21       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.